Cue Biopharma, Inc.
CUE
$0.56
-$0.01-1.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -27.25% | 601.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.25% | 601.66% | |||
| Cost of Revenue | -94.58% | 3.44% | |||
| Gross Profit | 134.71% | 31.41% | |||
| SG&A Expenses | 50.56% | -27.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.36% | -8.89% | |||
| Operating Income | 12.63% | 29.79% | |||
| Income Before Tax | 12.19% | 30.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.19% | 30.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.19% | 30.80% | |||
| EBIT | 12.63% | 29.79% | |||
| EBITDA | 12.56% | 30.02% | |||
| EPS Basic | 16.99% | 46.15% | |||
| Normalized Basic EPS | 17.48% | 46.22% | |||
| EPS Diluted | 16.99% | 46.15% | |||
| Normalized Diluted EPS | 17.48% | 46.22% | |||
| Average Basic Shares Outstanding | 5.67% | 28.56% | |||
| Average Diluted Shares Outstanding | 5.67% | 28.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||